Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study

BORIS DOI
Publisher DOI
PubMed ID
39963134
Description
Cladribine tablets (CladT) represent an effective immune reconstitution therapy, administered in short treatment courses over two consecutive years. To better understand the amplitude of immune changes, we performed a comprehensive analysis during the 2-year study period for the entire MAGNIFY-MS population (N=270). In addition to lymphocyte kinetics, we studied intracellular cytokines serum proteins, and their associations with clinical outcomes. To put these changes into perspective, we analyzed transcriptional changes in T and B cells and associated biological pathways before and after each treatment course with CladT.
Date of Publication
2025-02-03
Publication Type
article
Language(s)
en
Contributor(s)
Wiendl, Heinz
Barkhof, Frederik
Montalban, Xavier
Achiron, Anat
Derfuss, Tobias
Hodgkinson, Suzanne
Prat, Alexandre
Leocani, Letizia
Schmierer, Klaus
Sellebjerg, Finn
Vermersch, Patrick
Jin, Hulin
Chudecka-głaz Anita
Kloetgen, Andreas
Dongdong, Lin
Gardner, Lidia
De Nicola Stefano
Additional Credits
Universitätsklinik für Neurologie - Neuroimmunologie
Series
Frontiers in Immunology
Publisher
Frontiers Media
ISSN
1664-3224
Related URL(s)
https://doi.org/10.48620/86583
Access(Rights)
open.access
Show full item